CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
548 produits trouvés pour "CDK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Riviciclib hydrochloride
CAS :Riviciclib hydrochloride (P276-00) is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Phase 2/3.Formule :C21H20ClNO5·HClDegré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :438.3Metralindole HCl
CAS :Metralindole is a reversible monoamine oxidase A (RIMA) inhibitor, it was investigated as a potential antidepressant.Formule :C15H18ClN3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :291.78CGP60474
CAS :CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.Formule :C18H18ClN5ODegré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :355.82Ref: TM-T14943
1mg34,00€2mg46,00€5mg71,00€1mL*10mM (DMSO)78,00€10mg92,00€25mg177,00€50mg314,00€100mg518,00€CDK9-IN-15
CAS :CDK9-IN-15: potent CDK9 inhibitor, blocks P-TEFb phosphorylation, inhibits transcription, reduces mRNA, induces tumor cell apoptosis.Formule :C16H11N3OSDegré de pureté :99.32%Couleur et forme :SolidMasse moléculaire :293.34Ref: TM-T60619
1mL*10mM (DMSO)44,00€5mg46,00€10mg71,00€25mg126,00€50mg180,00€100mg260,00€200mg364,00€Atuveciclib S-Enantiomer
CAS :Atuveciclib S-Enantiomer is a (S)-form of BAY-1143572; a potent, selective CDK9 inhibitor with an IC50 of 16 nM.Formule :C18H18FN5O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :387.43CDK2-IN-13
CAS :CDK2-IN-13: Potent CDK2 inhibitor, arrests cell cycle, induces apoptosis, IC50=12 µM, used in cancer research.Formule :C13H12ClN5Couleur et forme :SoildMasse moléculaire :273.72NSC 625987
CAS :NSC 625987, Selective CDK4 inhibitor (IC50=0.2 μM), >500-fold selectivity over CDK2, used for p16-associated tumor studies.Formule :C15H13NO2SDegré de pureté :99.01%Couleur et forme :SolidMasse moléculaire :271.33Ref: TM-T23092
1mg63,00€5mg137,00€1mL*10mM (DMSO)150,00€10mg215,00€25mg371,00€50mg595,00€100mg893,00€ARN22089
CAS :ARN22089 is an oral active CDC42 GTPase interaction inhibitor that blocks tumour growth in BRAF mutant mouse melanoma models and PDXs in vivo.Formule :C23H27N5Degré de pureté :98.37%Couleur et forme :SolidMasse moléculaire :373.49Ref: TM-T85727
1mg109,00€5mg260,00€1mL*10mM (DMSO)286,00€10mg385,00€25mg647,00€50mg964,00€100mg1.431,00€200mg1.963,00€Cdc7-IN-4
CAS :Cdc7-IN-4 is a potent inhibitor of Cdc7 kinase.Formule :C22H24F3N5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :479.45BAY-958
CAS :BAY-958 is a potent and selective inhibitor of PTEFb/CDK9.Formule :C17H16FN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :389.4TP1287
CAS :TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib.Formule :C21H21ClNO8PCouleur et forme :SolidMasse moléculaire :481.82Aloisine A
CAS :Aloisine A, a CDK/GSK-3 inhibitor with IC50: Cdk1/B-150nM, Cdk2/A-120nM, Cdk2/E-400nM, Cdk5/25-200nM, Cdk5/35-160nM, GSK-3α-500nM, GSK-3β-650nM, JNK-3-10μM.Formule :C16H17N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :267.33CLK1-IN-2
CLK1-IN-2: Metabolically stable, Clk1-selective inhibitor; IC50=1.7nM; useful in tumor, Duchenne MD, HIV-1, influenza research.Formule :C16H12Cl2N2O2SCouleur et forme :SolidMasse moléculaire :367.25CDK4/6-IN-8
CAS :CDK4/6-IN-8 (Compound 7p) is a selective inhibitor of CDK4 (IC50=5.01 nM) and CDK6 (IC50=3.97 nM).Formule :C18H18N6O5Couleur et forme :SolidMasse moléculaire :398.37NSC 693868
CAS :CDKs and GSK-3 inhibitorFormule :C9H7N5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :185.19(E/Z)-BIO-acetoxime
CAS :(E/Z)-BIO-acetoxime: potent GSK-3 α/β inhibitor; IC50: GSK-3α/β 10nM, CDK5/p25 2.4μM, CDK2/A 4.3μM, CDK1/B 63μM.Formule :C18H12BrN3O3Couleur et forme :SolidMasse moléculaire :398.21MFH290
CAS :MFH290 is a selective CDK12/13 inhibitor, covalently bonding with CDK12 Cys-1039, blocks Pol II CTD phosphorylation, and enhances olaparib's efficacy.Formule :C26H31N5O3S2Couleur et forme :SolidMasse moléculaire :525.69RP-106
CAS :RP-106 is an ATP-competitive inhibitor of CDK5/p25, CDK1/cyclin B, and GSK-3.Formule :C17H19N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :281.35CDK8-IN-10
CAS :CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.Formule :C25H15ClF3N5O3Couleur et forme :SolidMasse moléculaire :525.87CDK4/6-IN-12
CAS :CDK4/6-IN-12 inhibits CDK4/6 with IC50s of 592.3 nM & 3090 nM, useful in cancer research.Formule :C12H10N6Couleur et forme :SolidMasse moléculaire :238.25CCT068127
CAS :CCT068127 is a potent CDK2 and CDK9 inhibitor.Formule :C19H27N7OCouleur et forme :SolidMasse moléculaire :369.46(S)-CR8
CAS :(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.Formule :C24H29N7OCouleur et forme :SolidMasse moléculaire :431.53(S)-LY3177833 hydrate
CAS :(S)-LY3177833 ((S)-Example 2) hydrate, an orally active CDC7 kinase inhibitor, exhibits extensive in vitro anticancer efficacy.Formule :C16H14FN5O2Couleur et forme :SolidMasse moléculaire :327.31EGFR/HER2/CDK9-IN-2
CAS :EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.Formule :C23H20N4O5S2Couleur et forme :SolidMasse moléculaire :496.56Cdc7-IN-9
CAS :Cdc7-IN-9 can be used for the research of cancer which is a potent inhibitor of Cdc7 [1].Formule :C15H17N5OSCouleur et forme :SolidMasse moléculaire :315.39Cdc7-IN-14
CAS :Cdc7-IN-14 (compound 82) is a potent CDC7 inhibitor with an IC50 < 1 nM, promising for cancer research.Formule :C18H20N4O2SCouleur et forme :SolidMasse moléculaire :356.44KH-CB19
CAS :KH-CB19 is an effective and highly specific inhibitor of the CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4).Formule :C15H13Cl2N3O2Couleur et forme :SolidMasse moléculaire :338.19Ref: TM-T15657
2mgÀ demander5mgÀ demander25mgÀ demander50mgÀ demander100mgÀ demander1mL*10mM (DMSO)À demanderCDK8-IN-6
CAS :CDK8-IN-6 (compound 9) is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) (Kd: 13 nM), CDK8-IN-6 showed potential research value in AML cancers.Formule :C26H37ClN2Couleur et forme :SolidMasse moléculaire :413.04Ipivivint
CAS :Ipivivint: orally active, potent CLK inhibitor; hinders CLK1, CLK2, & CLK3; curbs Wnt signaling & SRSF phosphorylation for cancer research.Formule :C26H21FN8Couleur et forme :SolidMasse moléculaire :464.5FN-1501-propionic acid
CAS :FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.Formule :C25H27N9O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :517.54Cdc7-IN-3
CAS :Cdc7-IN-3 is a potent inhibitor of Cdc7 kinase.Formule :C20H22N4O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :398.41JTK-101
CAS :JTK-101 is a potent and selective Tat-dependent HIV-1 replication inhibitor.Formule :C25H23N3O3Couleur et forme :SolidMasse moléculaire :413.47Ulecaciclib
CAS :Ulecaciclib: oral, BBB-permeable CDK inhibitor; favorable pharmacokinetics; ki: 0.62 μM (CDK2/A), 3 nM (CDK6/D3), 0.2 nM (CDK4/D1), 0.63 μM (CDK7/H).Formule :C25H33FN8SCouleur et forme :SolidMasse moléculaire :496.65Cdc7-IN-13
CAS :Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].Formule :C18H20N4O2SCouleur et forme :SolidMasse moléculaire :356.44CDK4/6-IN-9
CAS :CDK4/6-IN-9 selectively inhibits CDK4/6 (IC50: 905 nM); potential for MM research.Formule :C22H23FN8Couleur et forme :SolidMasse moléculaire :418.47CDK1-IN-1
CAS :CDK1-IN-7 inhibits CDK1 at 161.2 nM, triggers p53-dependent apoptosis, and selectively targets tumor growth.Formule :C27H23N5O3Couleur et forme :SolidMasse moléculaire :465.5Indirubin-5-sulfonate
CAS :Indirubin-5-sulfonate inhibits GSK-3β & CDKs with IC50: 55/35/150/300/65 nM for CDK1/B, 2/A&E, 4/D1, 5/p35.Formule :C16H10N2O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :342.33CDK7-IN-8
CAS :CDK7-IN-8 is a potent inhibitor of CDK7 (IC50: 54.29 nM) and exhibits inhibitory activity against several cancer cells and in vivo tumor models.Formule :C25H38N8O3Couleur et forme :SolidMasse moléculaire :498.62FLT3/CDK4-IN-1
CAS :FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.Formule :C25H28F2N8Couleur et forme :SolidMasse moléculaire :478.54CDK7-IN-20
CDK7-IN-20: potent, irreversible CDK7 inhibitor, IC50 of 4nM, 206x selectivity vs. other CDKs, potential for ADPKD study.Formule :C30H26N6O3Couleur et forme :SolidMasse moléculaire :518.57CDK7-IN-13
CAS :CDK7-IN-13 (compound 1) is an effective CDK7 inhibitor for investigating cancers associated with transcriptional dysregulation.Formule :C20H23F3N6OSDegré de pureté :99.22%Couleur et forme :SolidMasse moléculaire :452.5Indirubin-3'-monoxime-5-sulphonic acid
CAS :Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1 with IC50s of 80nM,5 nM, and 7 nM, respectively.Formule :C16H11N3O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :357.34BSJ-01-175
CAS :BSJ-01-175: Selective, potent covalent inhibitor of CDK12/13, targets cancer cells, inhibits phosphorylated RNA polymerase II, downregulates CDK12 genes.Formule :C30H33ClN6O2Couleur et forme :SolidMasse moléculaire :545.08MDK6204
CAS :MDK6204 is a selective inhibitor of CLK1 and CLK2.Formule :C20H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :360.41XIE18-6
CAS :XIE18-6 is a novel INK4C inhibitor that blocks p18 activity and promotes ex vivo expansion of human and murine hematopoietic stem cells.Formule :C18H15NO6SDegré de pureté :99.712%Couleur et forme :SolidMasse moléculaire :373.38CDK4/6-IN-14
CAS :CDK4/6-IN-14: potent CDK4/6 inhibitor, IC50s 10/16 nM, >60-fold selectivity over CDKs 1/2/7/9, selective across 205 kinases.Formule :C24H27ClFN7OCouleur et forme :SolidMasse moléculaire :483.97EGFR/HER2/CDK9-IN-1
CAS :EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.Formule :C23H21N3O3S2Couleur et forme :SolidMasse moléculaire :451.56CDK7-IN-2
CAS :CDK7-IN-2 inhibits CDK7, essential for RNA polymerase II activation and cell cycle control, with cancer research potential.Formule :C26H39N7O3Couleur et forme :SolidMasse moléculaire :497.63CDK4/6-IN-7
CAS :CDK4/6-IN-7 is an oral, potent CDK4/6 inhibitor with IC50s of 1.58/4.09 nM, crucial for breast cancer studies.Formule :C18H18ClN5O3Couleur et forme :SolidMasse moléculaire :387.82CDK7-IN-12
CAS :CDK7-IN-12 inhibits CDK7 to control transcription and cell cycle, halting tumor growth in vitro/vivo with cancer research potential.Formule :C20H19F3N6Couleur et forme :SolidMasse moléculaire :400.4
